SEC Comment Letter for IGC Pharma, Inc. (IGC) (CIK 0001326205) (IGC) — Sep 9, 2008

IGC Pharma, Inc. (IGC) (CIK 0001326205)
Date: Sept. 9, 2008 · CIK: 0001326205 · Accession: 0000000000-08-045140

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

February 6, 2008

Author

Assistant Director

Form

UPLOAD

Company

IGC Pharma, Inc. (IGC) (CIK 0001326205)

Letter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549-7010

DIVISION OF CORPORATION FINANCE

February 6, 2008

Mr. Ram Mukunda President and Chief Executive Officer India Globalization Capital, Inc. 4336 Montgomery Avenue Bethesda, MD 20814 Re: India Globalization Capital, Inc. Preliminary Proxy Statement on Schedule 14A Filed November 23, 2007 Annual Report on Form 10-KSB for the fiscal year ended March 31, 2007 File No. 1-32830 Dear Mr. Mukunda: We have completed our review of the Schedule 14A, Form 10-KSB, and related filings and have no further comments at this time.

Very truly yours,
Pamela A. Long
Assistant Director

Show Raw Text

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549-7010

       DIVISION OF
CORPORATION FINANCE

February 6, 2008

 Mr. Ram Mukunda President and Chief Executive Officer India Globalization Capital, Inc. 4336 Montgomery Avenue Bethesda, MD 20814  Re: India Globalization Capital, Inc.  Preliminary Proxy Statement on Schedule 14A  Filed November 23, 2007  Annual Report on Form 10-KSB for the fiscal year ended March 31, 2007
File No. 1-32830
 Dear Mr. Mukunda:   We have completed our review of the Schedule 14A, Form 10-KSB, and related filings and have no further comments at this time.

Very truly yours,

Pamela A. Long
                                                                Assistant Director

SecProbe.io